The time to develop treatments for diabetic neuropathy

References

• Sinnreich M, Taylor BV, Dyck PJ. Diabetic neuropathies. Classification, clinical features, and pathophysiological basis. Neurologist. 2005;11:63–79.
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic Neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136–154.
   PubMed Web of Science ®Google Scholar
• Abbott CA, Malik RA, van Ross ERE. van Ross ERE Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34:2220–2224.
   PubMed Web of Science ®Google Scholar
• Iqbal Z, Azmi S, Yadav R, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Thera. 2018;40:828–849.
   Google Scholar
• Vinik AI, Maser RE, Mitchell BD, et al. Diabetic autonomic neuropathy. Diabetes Care. 2003 May;26(5):1553–1579.
   PubMed Web of Science ®Google Scholar
• Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care. 2004 Dec;27(12):2942–2947.
   PubMed Web of Science ®Google Scholar
• Foley JM. The cranial mononeuropathies. N Engl J Med. 1969 Oct 16;281(16):905–906.
   PubMed Web of Science ®Google Scholar
• Andrews KL, Dyck PJ, Kavros SJ, et al. Plantar ulcers and neuropathic arthropathies: associated diseases, polyneuropathy correlates, and risk covariates. Adv Skin Wound Care. 2019 Apr;32(4):168–175.
   PubMed Web of Science ®Google Scholar
• Vinik A. Diabetic neuropathy: pathogenesis and therapy. Am J Med. 1999;107(2B):17S–26S.
   PubMedGoogle Scholar
• Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep. 2019;19:86.
   Web of Science ®Google Scholar
• Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester diabetic neuropathy study. Neurology. 1993;43:817–824.
   PubMed Web of Science ®Google Scholar
• Martin CL, Albers J, Herman WH, et al. DCCT/EDIC research group. neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006;29:340–344.
   PubMed Web of Science ®Google Scholar
• Martin CL, Albers JW, Pop-Busui R. DCCT/EDIC research group. neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:31–38. .
   PubMed Web of Science ®Google Scholar
• Maser RE, Steenkiste AR, Dorman JS, et al. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Epidemiological correlates of diabetic neuropathy. Diabetes. 1989;38:1456–1461.
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Chaturvedi N, Eaton SE, et al. EURODIAB prospective complications study group. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341–350.
   PubMed Web of Science ®Google Scholar
• Cavanagh JB. The ‘dying back’ process. a common denominator in many naturally occurring and toxic neuropathies. Arch Pathol Lab Med. 1979;103:659–664.
   PubMed Web of Science ®Google Scholar
• Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgrad Med J. 2006;82:95–100.
   PubMed Web of Science ®Google Scholar
• Edwards JL, Vincent A, Cheng T, et al. Diabetic neuropathy: mechanisms to management. Pharmacol Ther. 2008;120:1–34.
   PubMed Web of Science ®Google Scholar
• Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–1070.
   PubMed Web of Science ®Google Scholar
• Sundkvist G, Dahlin LB, H Nilsson H, et al. Sorbitol and myo-inositol levels and morphology of sural nerve in relation to peripheral nerve function and clinical neuropathy in men with diabetic, impaired, and normal glucose tolerance. Diabet Med. 2000;17:259–268.
   PubMed Web of Science ®Google Scholar
• Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides and Na+/K+ ATPase in the pathogenesis of diabetic complications. N Engl J Med. 1987;316:599–606.
   PubMed Web of Science ®Google Scholar
• Das EN, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res. 2007;55:498–510.
   PubMed Web of Science ®Google Scholar
• Williams B, Gallagher B, Patel H, et al. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes. 1997;46:1497–1503.
   PubMed Web of Science ®Google Scholar
• Stevens MJ, Feldman EL, Greene DA. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabet Med. 1995;12:566–579.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Dyck PJ. Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. Neurology. 1987;37:20–28.
   PubMed Web of Science ®Google Scholar
• Sima AA, Kamiya H. Diabetic neuropathy differs in type 1 and type 2 diabetes. Ann N Y Acad Sci. 2006;1084:235–249.
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Yokota Y, Tada J, et al. Diabetic neuropathy is closely associated with arterial stiffening and thickness in Type 2 diabetes. Diabet Med. 2007;24:1329–1335.
   PubMed Web of Science ®Google Scholar
• Finucane TE. Diabetic polyneuropathy and glucose control. JAMA. 2010;303:420–421.
   PubMed Web of Science ®Google Scholar
• Bennett M. The LANSS pain scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001;92:147–157.
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the neuropathic pain symptom inventory. Pain. 2004;108:248–257.
   PubMed Web of Science ®Google Scholar
• Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve. 1988;11:21–32.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneural sorbitol, fructose, and myo‐inositol related to sural nerve morphometry. Ann Neurol. 1980;8(6):590‐6.
   PubMed Web of Science ®Google Scholar
• Meijer JW, Smit AJ, Sonderen EV, et al. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the diabetic neuropathy symptom score. Diabet Med. 2002;19:962–965.
   PubMed Web of Science ®Google Scholar
• Perkins BA, Olaleye D, Zinman B, et al. The Toronto Clinical Neuropathy Score (TCNS) Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001;24:250–256.
   PubMed Web of Science ®Google Scholar
• Bril V, Tomioka S, Buchanan RA, et al. mTCNS study group. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med. 2009;26:240–246.
   PubMed Web of Science ®Google Scholar
• Herman WH, Pop-Busui R, Braffett BH, et al. Use of the Michigan neuropathy screening instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications. Diabet Med. 2012;29:937–944.
   PubMed Web of Science ®Google Scholar
• Young MJ, Boulton AJ, MacLeod AF, et al. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150–154.
   PubMed Web of Science ®Google Scholar
• Singleton JR, Bixby B, Russell JW. The Utah early neuropathy scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripheral Nerv Syst. 2008;13:218–227.
   PubMed Web of Science ®Google Scholar
• Zilliox LA,, Ruby SK, Singh S, et al. Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance. J Diabetes Complications. 2015;29:372–377.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Overland CJ, Low PA, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: cl vs. NPhys trial. Muscle Nerve. 2010;42:157–164.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Overland CJ, Low PA, et al. “Unequivocally abnormal” vs “usual” signs and symptoms for proficient diagnosis of diabetic polyneuropathy: cl vs N Phys Trial. Arch Neurol. 2012;69:1609–1614.
   PubMedGoogle Scholar
• Dyck PJ, Herrmann DN, Staff NP, et al. Assessing decreased sensation and increased sensory phenomena in diabetic polyneuropathies. Diabetes. 2013;62:3677–3686.
   PubMed Web of Science ®Google Scholar
• Burns TM, Taly A, O’Brien PC, et al. Clinical versus quantitative vibration assessment: improving clinical performance. J Peripher Nerv Syst. 2002;7:112–117.
   PubMed Web of Science ®Google Scholar
• Backonja MM, Attal N, Baron R, et al. Value of quantitative sensory testing in neurological and pain disorders: neuPSIG consensus. Pain. 2013;154:1807–1819.
   PubMed Web of Science ®Google Scholar
• Shy ME, Frohman EM, So YT, et al. Therapeutics and technology assessment subcommittee of the American Academy of Neurology. Quantitative sensory testing: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology. 2003;60:898–904.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Kratz KM, Lehman KA, et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology. 1991;41:799–807.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Argyros B, Russell JW, et al. Multicenter trial of the proficiency of smart quantitative sensation tests. Muscle Nerve. 2014;49:645–653.
   PubMed Web of Science ®Google Scholar
• Kincaid JC, Price KL, Jimenez MC, et al. Correlation of vibratory quantitative sensory testing and nerve conduction studies in patients with diabetes. Muscle Nerve. 2007;36:821–827.
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Boulton AJ, Dyck PJ, et al. Toronto diabetic neuropathy expert group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–2293.
   PubMed Web of Science ®Google Scholar
• Kong X, Lesser EA, Potts FA, et al. Utilization of nerve conduction studies for the diagnosis of polyneuropathy in patients with diabetes: a retrospective analysis of a large patient series. J Diabetes Sci Technol. 2008;2:268–274.
   PubMedGoogle Scholar
• Hyllienmark L, Alstrand N, Jonsson B, et al. Early electrophysiological abnormalities and clinical neuropathy. A prospective study in patients with type 1 diabetes. Diabetes Care. 2013;36:3187–3194.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, O’Brien PC, Litchy WJ, et al. Monotonicity of nerve tests in diabetes: subclinical nerve dysfunction precedes diagnosis of polyneuropathy. Diabetes Care. 2005 Sep;28(9):2192–2200.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Albers JW, Wolfe J, et al. A trial of proficiency of nerve conduction: greater standardization still needed. Muscle Nerve. 2013 Sep;48(3):369–374.
   PubMed Web of Science ®Google Scholar
• Litchy WJ, Albers JW, Wolfe J, et al. Proficiency of nerve conduction using standard methods and reference values (Cl. NPhys Trial 4). Muscle Nerve. 2014;50:900–908.
   PubMed Web of Science ®Google Scholar
• Malik RA. Diabetic neuropathy: A focus on small fibres. Diabetes Metab Res Rev. 2020;36(Suppl 1):e3255.
   PubMedGoogle Scholar
• Rendell MS, Katims JJ, Richter R, et al. A comparison of nerve conduction velocities and current perception thresholds as correlates of clinical severity of diabetic sensory neuropathy. J Neurol Neurosurg Psychiatry. 1989;52:502–511.
   PubMed Web of Science ®Google Scholar
• Kural MA, Pugdahl K, Fuglsang-Frederiksen A, et al. Near-nerve needle technique versus surface electrode recordings in electrodiagnosis of diabetic polyneuropathy.J. Clin Neurophysiol. 2016;33:346–349.
   Web of Science ®Google Scholar
• Lauria G, Lombardi R, Camozzi F, et al. Skin biopsy for the diagnosis of peripheral neuropathy. Histopathology. 2009;54:273–285.
   PubMed Web of Science ®Google Scholar
• Lauria G, Cornblath DR, Johansson O, et al. European federation of neurological societies. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol. 2005;12:747–758.
   PubMed Web of Science ®Google Scholar
• Divisova S, Vlckova E, Srotova I. Intraepidermal nerve-fibre density as a biomarker of the course of neuropathy in patients with Type 2 diabetes mellitus. Diabet Med. 2016;33:650–654.
   PubMed Web of Science ®Google Scholar
• Narayanaswamy H, Facer P, Misra VP, et al. A longitudinal study of sensory biomarkers of progression in patients with diabetic peripheral neuropathy using skin biopsies. J Clin Neurosci. 2012;19:1490–1496.
   PubMed Web of Science ®Google Scholar
• Løseth S, Stalberg EV, Lindal S, et al. Small and large fiber neuropathy in those with type 1 and type 2 diabetes: a 5-year follow-up study. J Peripher Nerv Syst. 2016;21:15–21.
   PubMed Web of Science ®Google Scholar
• Loseth S, Mellgren SI, Jorde R, et al. Polyneuropathy in type 1 and type 2 diabetes: comparison of nerve conduction studies, thermal perception thresholds and intraepidermal nerve fibre densities. Diabetes Metab Res Rev. 2010;26:100–106.
   PubMed Web of Science ®Google Scholar
• Asghar O, Petropoulos IN, Alam U, et al. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. Diabetes Care. 2014;37:2643–2646.
   PubMed Web of Science ®Google Scholar
• Alam U, Jeziorska M, Petropoulos IN, et al. Diagnostic utility of corneal confocal microscopy and intra-epidermal nerve fibre density in diabetic neuropathy. PLoS One. 2017;12:e0180175.
   PubMed Web of Science ®Google Scholar
• Tavakoli M, Petropoulos IN, Malik RA. Corneal confocal microscopy to assess diabetic neuropathy: an eye on the foot. J Diabetes Sci Technol. 2013;7:1179–1189.
   PubMedGoogle Scholar
• Young RJ, Ewing DJ, Clarke BF. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes. 1983;32:938–942.
   PubMed Web of Science ®Google Scholar
• Lewin G, O’Brien IA, Morgan MH, et al. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy. Diabetologia. 1984;26:445–448.
   PubMed Web of Science ®Google Scholar
• Sima AA, Bril V, Nathaniel V, et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med. 1988;319(9): 548–555.
   PubMed Web of Science ®Google Scholar
• Jaspan JB, Herold K, Bartkus C. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy. Am J Med. 1985 Nov 15;79(5A):24–37.
   PubMed Web of Science ®Google Scholar
• Sorbinil retinopathy trial research group. Sorbinil retinopathy trial research group the sorbinil retinopathy trial: neuropathy results. Neurology. 1993;43:1141–1149. .
   PubMed Web of Science ®Google Scholar
• Giugliano D, Acampora R, Marfella R, et al. Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care. 1995;18:536–541.
   PubMed Web of Science ®Google Scholar
• Macleod AF, Boulton AJ, Owens DR, et al. A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group. 1992;18:14–22. Diabete Metab.
   Google Scholar
• Santiago JV, P H Sonksen PH, A J Boulton AJ, et al. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group. J Diabetes Complications. 1993;7:170–178.
   PubMed Web of Science ®Google Scholar
• Ziegler D, P Mayer P, W Rathmann W, et al. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Pract. 1991;14:63–73.
   PubMed Web of Science ®Google Scholar
• Sundkvist G, Armstrong FM, Bradbury JE, et al. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. J Diabetes Complications. 1992;6:123–130.
   PubMedGoogle Scholar
• Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001;24:1776–1782.
   PubMed Web of Science ®Google Scholar
• Polydefkis M, Arezzo J, Nash M, et al. Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy. J Peripher Nerv Syst. 2015;20:363–371.
   PubMed Web of Science ®Google Scholar
• Sekiguchi K ,Kohara N,Masayuki BM. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan. J Diabetes Investig. 2019;10:466–474.
   PubMed Web of Science ®Google Scholar
• Goto Y, Hotta N, Shigeta Y, et al. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother. 1995;49:269–277.
   PubMed Web of Science ®Google Scholar
• Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care. 2006;29:1538–1544.
   PubMed Web of Science ®Google Scholar
• Crepaldi G, Fedele D, Tiengo A, et al. Ganglioside treatment in diabetic peripheral neuropathy: a multicenter trial. Acta Diabetol Lat. 1983;20:265–276.
   Google Scholar
• Abraham RR, Abraham RM, Wynn V. A double blind placebo controlled trial of mixed gangliosides in diabetic peripheral and autonomic neuropathy. Adv Exp Med Biol. 1984;174:607–624.
   PubMedGoogle Scholar
• Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci. 2001;24:1217–1281.
   PubMed Web of Science ®Google Scholar
• Longo FM, Holtzman DM, Grimes ML, et al. NGF: actions in the peripheral and central nervous systems. In: Loughlin SE, Fallen JHeditors. Neurotrophic Factors. San Diego, California: Academic Press; 1993. p. 209–256.
   Google Scholar
• Anand P, Terenghi G, Warner G, et al. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med. 1996;2:703–707.
   PubMed Web of Science ®Google Scholar
• Apfel SC, Kessler JA, Adornato BT, et al. and the NGF study group. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology. 1998;51:695–702.
   PubMed Web of Science ®Google Scholar
• Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA. 2000;284:2215–2221.
   PubMed Web of Science ®Google Scholar
• Lewin G, Mendell IM. Nerve growth factor and nociception. Trends Neurosci. 1993;16:353–359.
   PubMed Web of Science ®Google Scholar
• Cotter MA, Ekberg K, Wahren J, et al. Effects of proinsulin C-peptide in experimental diabetic neuropathy. Vascular actions and modulation by nitric oxide synthase inhibition. Diabetes. 2003;52:1812–1817.
   PubMed Web of Science ®Google Scholar
• Ekberg K, Brismar T, Johansson BL, et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care. 2007;30:71–76.
   PubMed Web of Science ®Google Scholar
• Wahren J, Foyt H, Daniels MM, et al. Long-acting C-peptide and neuropathy in type 1 diabetes: A 12-month clinical trial. Diabetes Care. 2016;39(4):596–602.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 Trial. Diabetes Care. 2011;34:2054–2060.
   PubMed Web of Science ®Google Scholar
• Casellini CM, Barlow PM, Rice AL. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care. 2007;30:896–902.
   PubMed Web of Science ®Google Scholar
• Vinik A, Bril V, Kemplar P, et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1 year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther. 2005;27:1164–1180.
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Tandan R, Bastyr EJ. Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care. 2007;30:2626–2632.
   PubMed Web of Science ®Google Scholar
• Dyck PJ. Methodology for conduct of epidemiologic surveys and randomized controlled trials of diabetic polyneuropathy. Handb Clin Neurol. 2014;126:335–338.
   PubMedGoogle Scholar
• Bril V. The perfect clinical trial. Int Rev Neurobiol. 2016;127:27–41.
   PubMed Web of Science ®Google Scholar
• Malik RA. Wherefore art thou, O treatment for diabetic neuropathy? Int Rev Neurobiol. 2016;127:287–317.
   PubMed Web of Science ®Google Scholar
• Sadosky A, McDermott AM, Brandenburg NA, et al. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract. 2008;8:45–56.
   PubMedGoogle Scholar
• Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy. Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1758–1765.
   PubMed Web of Science ®Google Scholar
• Patil PR, Wolfe J, Said Q, et al. Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population. Clin J Pain. 2015;31:414–424.
   PubMed Web of Science ®Google Scholar
• Joss JD. Tricyclic antidepressant use in diabetic neuropathy. Ann Pharmacother. 1999;33:996–1000.
   PubMed Web of Science ®Google Scholar
• Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250–1256.
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Bjerre U, Dejgaard A. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992;52:547–552.
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Grodum E, Gram LF, et al. Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study. Ther Drug Monit. 1991;13:408–414.
   PubMed Web of Science ®Google Scholar
• Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med. 2006;9:29–40.
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110:697–706.
   PubMed Web of Science ®Google Scholar
• Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med. 2019;179:695–701.
   PubMed Web of Science ®Google Scholar
• Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831–1836.
   PubMed Web of Science ®Google Scholar
• Philip J, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;2017(6):CD007938
   Google Scholar
• Parsons B, Li C, Emir B, et al. The efficacy of pregabalin for treating pain associated with diabetic peripheral neuropathy in subjects with type 1 or type 2 diabetes mellitus. Curr Med Res Opin. 2018;34):2015–2022.
   Web of Science ®Google Scholar
• Javed S, Uazman A, Malik RA. Mirogabalin and emerging therapies for diabetic neuropathy. J Pain Res. 2018;11:1559–1566.
   PubMed Web of Science ®Google Scholar
• Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD010111.
   Google Scholar
• Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107:490–502. .
   PubMed Web of Science ®Google Scholar
• Wolff RF, Bala MM, Westwood M, et al. 5% lidocaine-medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly. 2010;140:297–306.
   PubMed Web of Science ®Google Scholar
• Gudin J, Nalamachu S. Utility of lidocaine as a topical analgesic and improvements in patch delivery systems. Postgrad Med. 2020;132(1):28–36.
   PubMed Web of Science ®Google Scholar
• Yuen KCJ, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care. 2002;25:1699–1703.
   PubMed Web of Science ®Google Scholar
• Campbell CM, Kipnes M, Stouch BC. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153:1815–1823.
   PubMed Web of Science ®Google Scholar
• Wrzosek A1, Woron J, Dobrogowski J, et al. Topical clonidine for neuropathic pain. Cochrane Database Syst Rev. 2015;8:CD010967.
   PubMed Web of Science ®Google Scholar
• Freo U, Romualdi P, Kress HG. Tapentadol for neuropathic pain: a review of clinical studies. J Pain Res. 2019;12:1537–1551. .
   PubMed Web of Science ®Google Scholar
• Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1999;199(50):1842–1846
   Google Scholar
• Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997;48:1212–1218.
   PubMed Web of Science ®Google Scholar
• Sang CN, Booher S, Gilron I, et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology. 2002;96:1053–1061.
   PubMed Web of Science ®Google Scholar
• Shaibani A, Pope LE, Thisted R, et al. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study. Pain Med. 2012;13:243–254.
   PubMed Web of Science ®Google Scholar
• Patel MK, Kaye AD, Urman RD. Tanezumab: therapy targeting nerve growth factor in pain pathogenesis. J Anaesthesiol Clin Pharmacol. 2018;34:111–116.
   PubMed Web of Science ®Google Scholar
• Brown MT, Herrmann DN, Goldstein M, et al. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J Neurol Sci. 2014;345:139–147.
   PubMed Web of Science ®Google Scholar
• Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012;18:1430–1436.
   PubMed Web of Science ®Google Scholar
• Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015;20:658–666.
   PubMed Web of Science ®Google Scholar
• Gossrau G, Wähner M, Kuschke M, et al. Microcurrent transcutaneous electric nerve stimulation in painful diabetic neuropathy: a randomized placebo-controlled study. Pain Med. 2011;12:953–960.
   PubMed Web of Science ®Google Scholar
• Upton GA, Tinley P, Al-Aubaidy H, et al. The influence of transcutaneous electrical nerve stimulation parameters on the level of pain perceived by participants with painful diabetic neuropathy: A crossover study. Diabetes Metab Syndr. 2017;11:113–118.
   PubMed Web of Science ®Google Scholar
• Kumar D, Marshall HJ. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care. 1997;20:1702–1705.
   PubMed Web of Science ®Google Scholar
• Pieber K, Herceg M, Paternostro-Sluga T. Electrotherapy for the treatment of painful diabetic peripheral neuropathy: A review. J Rehabil Med. 2010;42:289–295.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Norell JE, Tritschler H, et al. Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care. 2007;30:2619–2625.
   PubMed Web of Science ®Google Scholar
• Diebold M, Derfuss T. Immunological treatment of multiple sclerosis. Semin Hematol. 2016;53(Suppl 1):S54–7.
   PubMedGoogle Scholar
• Gholamzad M, Ebtekar M, Ardestani MS, et al. A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflamm Res. 2019;68:25–38.
   PubMed Web of Science ®Google Scholar
• Hartung DM. Economics and Cost-Effectiveness of multiple sclerosis therapies in the USA. Neurotherapeutics. 2017;14:1018–1026.
   PubMed Web of Science ®Google Scholar
• Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999;122(Pt 4):625–639.
   PubMed Web of Science ®Google Scholar
• Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain. 1999;122(Pt 10):1941–1950.
   PubMed Web of Science ®Google Scholar
• Cottrell DA, Kremenchutzky M, Rice GP, et al., The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain. 122(Pt 4): 641–647. 1999.
   PubMedGoogle Scholar
• Bin Sawad A, Seoane-Vazquez E, Rodriguez-Monguio R, et al. Evaluation of the expanded disability status scale and the multiple sclerosis functional composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses. Curr Med Res Opin. 2016;32:1969–1974.
   PubMed Web of Science ®Google Scholar
• Ravnborg M, Blinkenberg M, Sellebjerg F, et al. Responsiveness of the multiple sclerosis impairment scale in comparison with the expanded disability status scale. Mult Scler. 2005;11:81–84.
   PubMed Web of Science ®Google Scholar
• Tullman MJ, R J Oshinsky RJ, F D Lublin FD, et al. Clinical characteristics of progressive relapsing multiple sclerosis. Mult Scler. 2004;10:451–454.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Davies JL, Litchy WJ, et al. Longitudinal assessment of diabetic polyneuropathy using a composite score in the rochester diabetic neuropathy study cohort. Neurology. 1997;49:229–239.
   PubMed Web of Science ®Google Scholar
• Kobori M, Yagihashi S, Shiina N, et al. Four‐year sequential nerve conduction changes since first visit in Japanese patients with early type 2 diabetes. J Diabetes Investig. 2017;8:369–376.
   PubMed Web of Science ®Google Scholar
• Müller-Felber W, Landgraf R, Scheuer R, et al. Diabetic neuropathy 3 years after successful pancreas and kidney transplantation. Diabetes. 1993;42:1482–1486.
   PubMed Web of Science ®Google Scholar
• Kennedy WR, Navarro X, Goetz FC, et al. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med. 1990;12(322):1031–1037.
   Google Scholar
• Ang L, Jaiswal M, Martin C, et al. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14:528.
   PubMed Web of Science ®Google Scholar
• Rendell M. The path to approval of new drugs for diabetes. Expert Opin Drug Saf. 2013;12:195–207. .
   PubMed Web of Science ®Google Scholar